Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer
(MedPage Today) -- Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the phase III...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.